Verve Therapeutics, Inc. (VERV)

NASDAQ: VERV · IEX Real-Time Price · USD

6.64

-0.02 (-0.30%)

At close: Apr 19, 2024, 4:00 PM

6.50

-0.14 (-2.11%)

After-hours: Apr 19, 2024, 4:07 PM EDT

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	11.76	1.94	0	0	0
Revenue Growth (YoY)	505.77%	-	-	-	-
Gross Profit	11.76	1.94	0	0	0
Selling, General & Admin	49.94	37.53	18.87	5.26	2.5
Research & Development	184.95	130.1	68.2	35.37	11.14
Operating Expenses	234.88	167.63	87.07	40.63	13.64
Operating Income	-223.12	-165.69	-87.07	-40.63	-13.64
Other Expense / Income	-23.33	-8.35	33.25	5.08	5.66
Pretax Income	-199.79	-157.33	-120.31	-45.7	-19.3
Income Tax	0.28	0.05	0	0	0
Net Income	-200.07	-157.39	-120.31	-45.7	-19.3
Shares Outstanding (Basic)	64	54	27	2	1
Shares Outstanding (Diluted)	64	54	27	2	1
Shares Change	18.79%	101.04%	1094.26%	76.18%	-
EPS (Basic)	-3.12	-2.91	-4.48	-20.31	-15.11
EPS (Diluted)	-3.12	-2.91	-4.48	-20.31	-15.11
Free Cash Flow	-158.83	-135.56	-82.24	-38.69	-9.3
Free Cash Flow Per Share	-2.48	-2.51	-3.06	-17.19	-7.28
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-1897.64%	-8536.17%	-	-	-
Profit Margin	-1701.55%	-8108.55%	-	-	-
Free Cash Flow Margin	-1350.84%	-6984.23%	-	-	-
EBITDA	-187.55	-150.62	-116.94	-44.38	-19.19
EBITDA Margin	-1595.05%	-7760.07%	-	-	-
Depreciation & Amortization	12.25	6.71	3.38	1.33	0.11
EBIT	-199.79	-157.33	-120.31	-45.7	-19.3
EBIT Margin	-1699.21%	-8105.82%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).